Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pre- and Post- NACT ovarian cancer

ABSTRACT: Samples from 22 ovarian cancer patients before and again after neoadjuvant chemotherapy

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Ovary Cancer Cell

SUBMITTER: Mark Valentine

LAB HEAD: Mark Valentine

PROVIDER: PXD070494 | Pride | 2025-11-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	14i_search.xml	Xml
	14n_search.xml	Xml
	15i_search.xml	Xml
	15n_search.xml	Xml
	16i_search.xml	Xml

Items per page:

1 - 5 of 86

Publications

Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy-Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response.

Valentine Mark C MC Mullen Mary M MM Kotnik Emilee N EN Powell Matthew A MA Thaker Premal H PH McCourt Carolyn K CK Kuroki Lindsay M LM Hagemann Andrea R AR Arend Rebecca C RC Holehouse Alex S AS Mitra Robi R Mutch David G DG Fuh Katherine C KC

Cancer research 20250901 18

High-grade serous ovarian cancer (HGSC) accounts for more than 200,000 deaths each year. Despite recent advances in treating HGSC with neoadjuvant chemotherapy, the majority of patients ultimately develop chemotherapy resistance. HGSC is characterized by TP53 mutations and widespread copy-number alterations and occurs frequently in the setting of deleterious germline BRCA1/2 variations, but many cases lack putative driver mutations. In this study, we performed whole-exome, whole-genome, and whol ...[more]

PMID: 40693832

Similar Datasets

The immune response against cancer is modulated by stromal cell fibronectin

Project description:The data set compares murine bone marrow stromal cells that express osterix-cre (and hence cells in which the osterix promoter is active) to the cells isolated from the same animals that did not express osterix-cre (and hence do not activate the osterix promoter). To sort these cells, we used the reporter gene tdTomato. If the gene is present, the protein is not expressed because the gene is preceded by a STOP codon flanked by two floxed sites. If, on the other hand, cre is expressed (in this case osterix-cre) in the same cell that contains the tdTomato gene, activation of the promoter will lead to cre recombinase expression and removal of the gene part flanked by floxed sequences. This will remove the STOP codon and lead to expression of the tdTomato protein. Cells that are osterix-cre_tdTomatofloxed/+ therefore will express tdTomato and can be detected by flow cytometry allowing sorting. The cells were isolated from the bone marrow of adult mice. It should be noted, that in addition to the difference in osterix promoter activation, tdTomato is also expressed in the sorted osterix-cre cells. There are 4 samples that do not express osterix followed by 4 samples that do as follows: Control samples numbered 1-4 and Osterix samples numbered 5-8. Analysis results are summarized as supplementary figure 3 and supplementary table 1 in Lubosch, Pitt et al. 2025, Neoplasia

2025-06-20 | PXD065221 | Pride

Tailored phenyl ureas eradicate drug-resistant Mycobacterium tuberculosis by targeting mycolic acid cell wall assembly

Project description:Treatment of Mycobacterium tuberculosis infections is a challenging task due to a growing number of resistant clinical isolates as well as an almost empty drug development pipeline. To identify new antibiotic hits, we screened a focused library of 400 synthetic compounds derived from a recently discovered molecule with promising anti-mycobacterial activity. A suite of more potent hit molecules was deciphered with sub-micromolar activity. Utilising tailored affinity-based probes for chemical proteomic investigations, we successfully pinpointed the mycolic acid transporter MmpL3 and two epoxide hydrolases, EphD and EphF, also linked to mycolic acid biosynthesis, as specific targets of the compounds. These targets were thoroughly and independently validated by activity assays, under- and overexpression, resistance generation, and proteomic studies. Structural refinement of the most potent hit molecules led to the development of a new lead compound that demonstrates enhanced biological activity in M. tuberculosis, low human cytotoxicity, and improved solubility and oral bioavailability − traits that are often challenging to achieve with anti-mycobacterial drugs. Overall, drug-likeness, as well as the dual mode of action, addressing the mycolic acid cell wall assembly at two distinct steps, holds significant potential for further in vivo applications.

2025-05-06 | PXD050993 | Pride

TECPR2 HSAN9 Mutation Medulla analysis Mouse

Project description:Analysis of proteome changes in medulla in mice expressing a disease-mimicking TECPR2 variant

2025-10-23 | PXD065944 | Pride

Phosphoproteomics of Natural Killer (NK) Cells Stimulated with Fibrin and IL-15

Project description:Phosphoproteomic analysis of fibrin or IL-15 treated NK cells with timsTOF HT

2024-06-26 | PXD049692 | Pride

Malonylation of Acetyl-CoA Carboxylase 1 Promotes Hepatic Steatosis and Is Attenuated by Ketogenic Diet in NAFLD

Project description:Protein post-translational modifications (PTMs) participate in important bioactive regulatory processes and therefore can help elucidate the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Here, we investigate the involvement of PTMs in ketogenic diet (KD)-improved fatty liver by multi-omics and reveal a core target of lysine malonylation, acetyl-CoA carboxylase 1 (ACC1). ACC1 protein levels and Lys1523 malonylation are significantly decreased by KD. It is discovered that a malonylation-mimic mutant in ACC1 increases its enzyme activity and stability to promote hepatic steatosis, whereas the malonylation-null mutant upregulates the ubiquitination degradation of ACC1. A customized Lys1523ACC1 malonylation antibody confirms the increased malonylation of ACC1 in the NAFLD samples. Overall, the lysine malonylation of ACC1 is attenuated by KD in NAFLD and plays an important role in promoting hepatic steatosis. Malonylation is critical for ACC1 activity and stability, highlighting the anti-malonylation effect of ACC1 as a potential strategy for treating NAFLD.

2023-07-21 | PXD040481 | Pride

The RNA helicase Dbp10 coordinates assembly factor association with PTC formation during ribosome biogenesis

Project description:During ribosome biogenesis a plethora of assembly factors and essential enzymes drive the unidirectional maturation of nascent pre-ribosomal subunits. The DEAD-box RNA helicase Dbp10 is suggested to restructure pre-ribosomal rRNA of the evolving peptidyl-transferase center (PTC) on nucleolar ribosomal 60S assembly intermediates. Here, we show that point mutations within conserved catalytic helicase-core motifs of Dbp10 yield a dominant-lethal growth phenotype. Such dbp10 mutants, which stably associate with pre-60S intermediates, impair pre-60S biogenesis at a nucleolar stage prior to the release of assembly factor Rrp14 and stable integration of late nucleolar factors such as Noc3. Furthermore, the binding of the GTPase Nug1 to particles isolated directly via mutant Dbp10 bait proteins is specifically inhibited. The N-terminal domain of Nug1 interacts with Dbp10 and the methyltransferase Spb1, whose pre-60S incorporation is also reduced in absence of functional Dbp10. Our data suggest that Dbp10’s helicase activity generates a crucial framework for assembly factor docking thereby permitting the progression of pre-60S maturation

2024-05-22 | PXD046068 | Pride

Liver-Targeted siRNA Therapy Reveals a Causal Role of Metabolic Dysfunction-Associated Steatotic Liver Disease in Brain Dysfunction

Project description:Metabolic-dysfunction-associated steatotic liver disease (MASLD) has traditionally been studied as a liver-centric condition. However, growing clinical and experimental evidence reveals a strong link between MASLD and cognitive impairment and sensorimotor alterations. The mechanisms underlying this liver-brain axis remain poorly defined, and whether hepatic dysfunction alone is sufficient to drive central nervous system deficits is unclear. Using diet-induced non-obese mouse models of MASLD, we performed comprehensive neurocognitive and behavioral assessments. MASLD was associated with marked alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished indicators of neurogenesis in the hippocampal dentate gyrus. Then, we selectively modulated liver metabolism through a hepatocyte-targeted siRNA therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD, employing GalNAc-siRNA technology for targeted delivery. Notably, liver-specific intervention with siRNA-CNNM4 reversed features of impaired social memory and sensorimotor processing through recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Importantly, hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis. These results open new avenues for treating MASLD-associated neurological complications through liver-directed therapies.

2025-09-22 | PXD063321 | Pride

Proteomic profile of BxPC3 cells after RAD51 inhibition by treatment with BRC4

Project description:RAD51 protein is an evolutionarily conserved recombinase that plays a central role in homologous recombination (HR) and DNA double strand break (DSB) repair. RAD51 inactivation by small molecules has been proposed as a strategy to impair the BRCA2/RAD51 binding and, ultimately, the HR pathway, with the aim to make cancer cells more sensitive to PARP inhibitors (PARPi). This strategy, which mimics a synthetic lethality (SL) approach, has been successfully assayed in vitro by using myr-BRC4, a peptide derived from the fourth BRC repeat of BRCA2, being the strongest reported natural RAD51 binder. The present study applies a method to obtain a proteomic fingerprint for RAD51 inhibition by the myr-BRC4 peptide (designed for a more efficient cell entry) using a mass spectroscopy (MS) proteomic approach. We performed a comparative proteomic profiling of the myr-BRC4 treated vs. untreated BxPC-3 pancreatic cancer cells and evaluated the differential expression of proteins. Among the identified proteomic hits, we focused our attention on proteins shared by both the RAD51 and the BRCA2 interactomes, and on those whose reduction showed high statistical significance. Three downregulated proteins were identified (FANCI, FANCD2, and RPA3) and protein downregulation was confirmed through immunoblotting analysis, validating the MS approach. Our results suggest that, being a direct consequence of RAD51 inhibition, the detection of FANCD2, FANCI, and RPA3 downregulation could be used as an indicator for monitoring HR impairment.

2023-08-15 | PXD042696 | Pride

Full proteome analysis of Chlorotonil treated S. aureus

Project description:Part of manuscript for the identifiaction of the cellular targets of Chlorotonil and its derivatives,

2025-03-08 | PXD051735 | Pride

Cryo-EM structures of Gid12-bound GID E3 reveal steric blockade as a mechanism inhibiting substrate ubiquitylation

Project description:Protein degradation, a major eukaryotic response to cellular signals, is subject to numerous layers of regulation. In yeast, the evolutionarily conserved GID E3 ligase mediates glucose-induced degradation of fructose-1,6-bisphosphatase (Fbp1) and other gluconeogenic enzymes. “GID” is a collection of E3 ligase complexes; a core scaffold, RING-type catalytic core and supramolecular module along with interchangeable substrate receptors select targets for ubiquitylation. However, knowledge of additional cellular factors directly regulating GID-type E3s remains rudimentary. Here, we structurally and biochemically characterize Gid12 as a modulator of the GID E3 ligase complex targeting Fbp1. Our collection of cryo-EM reconstructions shows that Gid12 forms an extensive interface sealing the substrate receptor Gid4 onto the scaffold, and remodeling the degron binding site. Gid12 also sterically blocks a recruited Fbp1 from the ubiquitylation active sites. Our analysis of the role of Gid12 establishes principles that may more generally underlie E3 ligase regulation.

2022-05-29 | PXD028579 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data